Integrated Advisors Network LLC Raises Stock Holdings in Amgen Inc. $AMGN
Integrated Advisors Network LLC significantly increased its stake in Amgen Inc. by 50.5% in the first quarter, now holding shares worth approximately $6.66 million. This move is part of a broader trend of high institutional ownership in Amgen, with other major firms also adding to their positions. Despite mixed analyst ratings, with some upgrades and price target increases alongside "Hold" recommendations, several key headlines are impacting investor sentiment, including regulatory scrutiny and pipeline prospects.
Kiley Juergens Wealth Management LLC Takes $1.25 Million Position in Amgen Inc. $AMGN
Kiley Juergens Wealth Management LLC has acquired a new position in Amgen Inc. (NASDAQ:AMGN) during the first quarter, purchasing 3,566 shares valued at approximately $1.25 million. This move comes as other institutional investors have also modified their holdings in Amgen. The company reported strong Q1 earnings, beating estimates, though investor sentiment remains cautious regarding certain drug scrutinies and pipeline questions.
Hodges Capital Management Inc. Increases Stock Holdings in Amgen Inc. $AMGN
Hodges Capital Management Inc. significantly increased its stake in Amgen Inc. by 75.4% in the first quarter, purchasing an additional 3,620 shares to bring its total holdings to 8,424 shares valued at $2.96 million. This increase follows strong quarterly results from Amgen, with EPS of $5.15 and revenue of $8.62 billion beating estimates, leading the company to raise its full-year 2026 guidance. Despite a "Hold" consensus from analysts, sentiment is mixed, with some upgrades and price target increases, though concerns persist regarding Tavneos scrutiny and relative stock underperformance.
Jefferies downgrades Medpace stock rating on valuation concerns By Investing.com
Jefferies downgraded Medpace Holdings Inc. (NASDAQ:MEDP) to Hold from Buy due to valuation concerns, despite raising its price target to $515.00 from $490.00. The stock is currently trading significantly above this new target, and InvestingPro data indicates it is overvalued, with shares trading at high earnings multiples. Analysts are also concerned by recent earnings downgrades and an increase in cancellations within Medpace's backlog, which could lead to multiple compression if out-year estimates are reduced.
Biogen Inc (MEX:BIIB) Stock Price, Trades & News
This article provides a detailed stock summary page for Biogen Inc (MEX:BIIB), covering its current stock price, key financial metrics like P/E ratio, market cap, and enterprise value. It also includes an overview of the company's business description as a biopharmaceutical firm focused on neurodegenerative and rare diseases, along with various financial strength, growth, profitability, and valuation ranks. The page highlights warning signs detected by GuruFocus and lists upcoming stock events and recent press releases related to the company.
2026 Best Places to Work in Kentucky rankings announced
The Kentucky Chamber of Commerce and SHRM Kentucky honored 100 companies at the 22nd annual Best Places to Work in Kentucky awards ceremony. Amgen Inc., L&N Federal Credit Union, and Wehr Constructors, Inc., were recognized as top-ranked companies in the large, medium, and small categories, respectively. These rankings highlight companies dedicated to improving workplace environments and making Kentucky a great place to live and work.
FDMT - 4D Molecular Therapeutics Inc Revenue Breakdown
This article provides a detailed financial breakdown for 4D Molecular Therapeutics Inc. (FDMT), including key metrics such as market cap, sales, income, EPS, and various performance indicators. It also lists insider and institutional ownership, short interest, and analyst recommendations.
AMGN Reiterated by Cantor Fitzgerald -- Price Target Maintained at $350
Cantor Fitzgerald analyst Carter Gould has maintained a Neutral rating for Amgen (AMGN) with an unchanged price target of $350.00, reflecting a stable outlook for the company. GuruFocus indicates that AMGN is currently 5.8% overvalued with a GF Value of $353.64 and a current price of $374.15, despite having a strong GF Score of 88/100, driven by excellent profitability and growth. Insider activity shows $0.4 million in shares sold over the last three months, suggesting investors should exercise caution.
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $350
Cantor Fitzgerald has reiterated a Neutral rating on Amgen Inc. (NASDAQ:AMGN) with a $350 price target, despite expectations of a strong quarterly earnings driven by Repatha and Uplizna performance. The firm noted that Amgen's pipeline lacks significant drivers to extend its recent stock momentum, which has seen shares rise over 10% since June. While InvestingPro analysis suggests Amgen is undervalued with a Fair Value of $394, Cantor Fitzgerald believes a good earnings report alone won't lead to a substantial re-rating given upcoming patent expirations and other pipeline issues.
Amgen Inc. $AMGN Shares Bought by Stephens Inc. AR
Stephens Inc. AR increased its stake in Amgen Inc. by 8.6% in the first quarter of 2026, acquiring an additional 9,094 shares, bringing its total holding to 114,544 shares valued at approximately $40.6 million. Amgen also reported strong quarterly earnings, beating analyst estimates with $5.15 EPS on $8.62 billion in revenue, representing a 5.8% year-over-year growth. Despite mixed analyst ratings, with a consensus "Hold" and an average price target of $355.50, several firms have reaffirmed or raised their price targets to as high as $400.
Dividend Assets Capital LLC Sells 9,002 Shares of Amgen Inc. $AMGN
Dividend Assets Capital LLC decreased its holdings in Amgen Inc. by 20.1% in the first quarter, selling 9,002 shares and retaining 35,864 shares valued at approximately $12.6 million. Despite the reduction by this firm, other hedge funds increased their stakes in Amgen. The medical research company reported strong Q1 earnings, with EPS of $5.15 and revenue of $8.62 billion, surpassing analyst estimates.
Amgen Inc. Stock 12‑Month Price Target Raised to $355.04, Implies 5% Downside
The average 12-month price target for Amgen Inc. (AMGN) stock has been raised by analysts from $352.35 to $355.04. This updated target, based on the Jul. 2 closing price, implies a potential 5% downside for the stock. Despite this, the consensus rating from 35 analysts remains "Buy," with 14 Buys, 17 Holds, and 4 Sells.
Ascentis Independent Advisors Acquires 8,192 Shares of Amgen Inc. $AMGN
Ascentis Independent Advisors significantly increased its stake in Amgen Inc. by 153.2% in the first quarter, adding 8,192 shares to reach a total of 13,541 shares valued at approximately $4.77 million. Amgen reported strong quarterly earnings, with EPS of $5.15 and revenue of $8.62 billion, exceeding analyst estimates. Despite mixed analyst sentiment and insider share sales, the company reiterated its full-year 2026 EPS guidance.
Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion
Novartis AG has agreed to acquire British biotech Myricx Bio for up to $1.5 billion. This acquisition aims to bolster Novartis's cancer drug portfolio with Myricx's experimental therapies that target tumors specifically, minimizing harm to healthy cells. Myricx shareholders are set to receive $1.1 billion upfront, with an additional $400 million in potential milestone payments.
5 molecular glues that could stick—and the companies stuck in
Molecular glue degraders are gaining significant traction in drug development for treating "undruggable" cancers and immunological diseases, attracting substantial funding and partnerships from major pharmaceutical companies. This article highlights five clinical programs from Bristol Myers Squibb, Monte Rosa Therapeutics, C4 Therapeutics, Neomorph, and Degron Therapeutics, showcasing their innovative approaches and the potential for these molecules to revolutionize treatment options. The use of AI in discovering novel targets is accelerating this field, creating new therapeutic avenues.
Amgen (AMGN) Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap
Amgen's stock is gaining momentum after a federal judge blocked Colorado's proposed 70% price cap on its key drug, Enbrel, removing a significant regulatory threat. While one fair value estimate suggests Amgen is modestly overvalued, a Discounted Cash Flow (DCF) model indicates it could be trading 45.33% below its intrinsic value. Investors are encouraged to review the valuation numbers and consider both the opportunities and risks, including potential drug pricing pressures and biosimilar competition.
ARGX - Argen X SE ADR Options
This article provides a comprehensive overview of Argen X SE ADR (ARGX) stock, including its last closing price, financial performance metrics, and various stock indicators. It details market capitalization, income, sales, P/E ratios, EPS, insider and institutional ownership, profitability, and stock performance over different periods. The data also includes analyst recommendations and target prices.
VRTX - Vertex Pharmaceuticals Inc Options
This article provides a detailed financial overview of Vertex Pharmaceuticals Inc (VRTX), including its stock performance, market capitalization, income, sales, and various financial ratios. It also highlights institutional and insider ownership, profitability margins, and analyst recommendations, offering a comprehensive snapshot of the company's financial health and market position.
Amgen Stock: What Happened After a Judge Blocks Colorado’s Enbrel Price Cap?
Amgen stock saw a 3.55% jump after a federal judge blocked Colorado's price cap on its arthritis drug Enbrel, which generated $2.23 billion in 2025 sales. Despite this win, Amgen faces a significant patent cliff and regulatory overhangs for other drugs. Analysts have a mixed consensus with a mean target below the current price, but TIKR's model projects a 25% total return by 2030, contingent on growth drivers offsetting declines from expiring patents.
Vivid Wealth Management LLC Invests $2.46 Million in Amgen Inc. $AMGN
Vivid Wealth Management LLC has invested $2.46 million in Amgen Inc. by purchasing 6,987 shares during the first quarter. This investment comes as Amgen posted strong first-quarter results, exceeding EPS and revenue expectations. Analysts currently have a "Hold" rating on Amgen, with a consensus price target of $355.50.
GMAB - Genmab ADR Earnings
This Finviz article provides a detailed financial overview of Genmab ADR (GMAB), including its last closing price, key financial metrics like market cap, income, sales, P/E ratio, and EPS. It also lists performance indicators, insider ownership, institutional ownership, and analyst recommendations. The data highlights recent stock performance and valuation figures for the biotechnology company.
Amgen Inc. $AMGN Shares Purchased by QRG Capital Management Inc.
QRG Capital Management Inc. increased its stake in Amgen Inc. by 20.5% during the first quarter, now holding 94,383 shares valued at over $33 million. Other institutional investors also adjusted their positions in Amgen, with a significant majority of the stock (76.50%) owned by institutions and hedge funds. Wall Street analysts have provided a mixed outlook, with an average "Hold" rating and a target price of $355.50, while an Amgen SVP recently sold a portion of their shares.
Boston Trust Walden Corp Purchases 12,647 Shares of Amgen Inc. $AMGN
Boston Trust Walden Corp increased its stake in Amgen Inc. by 17.6% in the first quarter, purchasing 12,647 additional shares to own a total of 84,552 shares valued at $29.75 million. Amgen also reported strong first-quarter earnings, with EPS of $5.15 and revenue of $8.62 billion, surpassing analyst expectations. Despite a "Hold" average rating from analysts, some firms have recently raised their price targets and issued bullish recommendations for the stock.
If You Invested $1,000 in Cytomx Therapeutics Inc (CTMX)
This article analyzes the historical performance of a $1,000 investment in Cytomx Therapeutics Inc (CTMX) over different periods, including 1, 5, and 10 years, and since October 2015. It also provides a detailed company profile, outlining CytomX's focus on conditionally activated biologics for oncology, its proprietary PROBODY® platform, clinical pipeline, and collaborations. The data shows significant volatility and overall negative returns over longer periods, contrasting with a strong gain in the last year.
Liquidia Corp outlines path in pulmonary hypertension as investors watch regulatory milestones
Liquidia Corp is leveraging its proprietary drug delivery technology to develop therapies for pulmonary hypertension, with a focus on optimizing existing treatments. Investors are closely monitoring regulatory milestones, such as clinical trial data and FDA approvals, and commercialization progress, including market access and funding, which are crucial for the company's long-term growth in this specialized biopharmaceutical sector. The company's stock represents a typical risk-reward profile for a development-stage biotech, with performance tied to regulatory decisions and commercial readiness.
Argenx SE outlines growth path in rare disease therapies
Argenx SE, a biotechnology company, is focusing on building a global franchise in autoimmune and rare disease treatments using antibody-based therapies. The company aims to expand its presence in major markets, including the United States, through a blend of internal research and strategic collaborations. Its strategy emphasizes specialized antibody platforms to address hard-to-treat indications, particularly focusing on autoimmune and neuromuscular diseases, with the goal of shifting revenue from milestones to recurring product sales.
CCLD - CareCloud Inc Short Interest
The article provides a detailed snapshot of CareCloud Inc. (CCLD) as of July 2, with its last close at $2.22 and a slight decrease of 2.20%. It includes comprehensive financial data, performance metrics, and short interest figures for the company. Key data points cover market capitalization, P/E ratio, sales, insider and institutional ownership, and year-to-date performance.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak US jobs report in June, investors are shifting focus to healthcare stocks, moving away from semiconductor and AI sectors. This article highlights three healthcare companies—Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD)—that are well-positioned for resilience amidst economic uncertainties. Each company offers unique strengths, from pipeline advancements and recurring revenue models to strong market presence and dividends, making them attractive in the current investment climate.
Y Intercept Hong Kong Ltd Takes $11.40 Million Position in Amgen Inc. $AMGN
Y Intercept Hong Kong Ltd initiated a significant position in Amgen Inc. during the first quarter, purchasing 32,401 shares valued at approximately $11.4 million. This move comes as Amgen reports strong earnings, surpassing expectations with $5.15 EPS and $8.62 billion in revenue, marking a 5.8% year-over-year growth. Despite a "Hold" consensus rating from analysts, several firms have either raised their price targets or upgraded the stock, reflecting varied sentiment but ongoing interest in the biotechnology giant.
Amgen Inc. $AMGN Shares Sold by Peregrine Asset Advisers Inc.
Peregrine Asset Advisers Inc. significantly reduced its stake in Amgen (NASDAQ:AMGN) by 82.1% in the first quarter, now holding 2,801 shares valued at $986,000. Amgen is navigating mixed challenges, including a favorable ruling against a drug price cap for Enbrel but also facing scrutiny after a medical journal retracted a pivotal paper for Tavneos. Despite these, the company reported strong Q1 earnings and continues to have a robust pipeline, leading analysts to maintain a "Hold" rating with a consensus target price of $355.50.
Strs Ohio Cuts Stake in Amgen Inc. $AMGN
Strs Ohio reduced its stake in Amgen Inc. by 7.3% in the first quarter, selling over 10,000 shares but still holding 128,783 shares valued at approximately $45.3 million. Amgen reported strong Q1 results, exceeding EPS and revenue expectations, and reaffirmed its full-year 2026 EPS guidance. Analyst sentiment remains largely positive, with an average "Hold" rating and a consensus price target of $355.50.
Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) has received FDA Fast Track designation for its Duchenne muscular dystrophy treatment, SAT-3247, aiming to accelerate its development. This designation, coupled with existing Orphan Drug and Rare Pediatric Disease designations, positions the company for significant potential in a Duchenne market projected to reach US$62.13 billion by 2030. Analysts have issued "Strong Buy" ratings for Satellos, with price targets ranging from US$11 to US$23, highlighting investor excitement for its ongoing Phase 2 studies.
AMGN - AMGEN Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for AMGEN Inc (AMGN). It covers various financial metrics, stock performance indicators, insider and institutional ownership details, as well as key valuation ratios and analyst recommendations. The information highlights AMGEN's recent financial health and market position.
Amgen Inc. $AMGN Shares Sold by Fideuram Intesa Sanpaolo Private Banking S.P.A.
Fideuram Intesa Sanpaolo Private Banking S.P.A. reduced its stake in Amgen Inc. by 32.5% in the first quarter, selling 22,287 shares and now owning 46,275 shares valued at $16.28 million. Despite this, other institutional investors increased their holdings, and Amgen received positive news regarding a federal judge blocking a price cap on Enbrel, pipeline advancements, and an increased price target from Mizuho due to potential new drugs. Analysts currently have a "Hold" rating on Amgen with an average price target of $355.50.
Novo Nordisk, the maker of Ozempic, is controlled by a Copenhagen charity that holds 77% of the voting power through special shares that have never been traded and legally can never be sold
Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy, is uniquely controlled by the Novo Nordisk Foundation, a Copenhagen-based charity. This foundation holds 77% of the voting rights through special A-shares that have never been traded and legally cannot be sold. This unusual structure ensures the company remains Danish, independent, and research-focused, with its substantial dividends directed towards scientific and humanitarian causes globally.
Revolution Medicines (RVMD) Reports Phase 1 2 Pancreatic Cancer Data That Sets Up Phase 3
Revolution Medicines (RVMD) has reported promising Phase 1/2 trial data for its RAS(ON) inhibitor combinations, zoldonrasib and daraxonrasib, in metastatic pancreatic cancer. The data showed strong antitumor activity and manageable safety, particularly in patients with RAS G12D mutation, positioning the company for pivotal Phase 3 trials in both first-line and previously treated settings. These results are significant given the current lack of approved targeted options for this mutation in pancreatic cancer.
Amgen, Sanofi Team Up To Urge En Banc Antibody IP Review
Rival pharmaceutical companies Amgen and Sanofi have jointly requested a full Federal Circuit review of a decision that revived migraine drug antibody patents. This comes despite their previous clash at the U.S. Supreme Court over antibody patents. The move highlights a shared interest in intellectual property matters within the pharmaceutical industry.
REGN - Regeneron Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial overview of Regeneron Pharmaceuticals Inc (REGN), including its latest stock performance, key financial metrics, and company statistics. It covers various aspects like market capitalization, income, sales, dividend information, analyst recommendations, and performance across different timeframes.
Harrow relaunches biosimilar Byooviz in the US
Harrow Inc. has re-launched BYOOVIZ (ranibizumab-nuna) in the U.S. commercial market, stemming from a partnership with Samsung Bioepis Co., Ltd. BYOOVIZ is an intravitreally-administered injection for treating wet age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. It was the first ophthalmic biosimilar approved by the FDA in 2021 and received interchangeable designation in 2023, allowing pharmacists to substitute it for the reference product, Lucentis, without a new prescription.
Should Alvotech’s Expanded US$240 Million Capital Access Require Action From Alvotech (ALVO) Investors?
Alvotech recently secured an additional US$75 million term loan, bringing its total new capital access to US$240 million, alongside a US$165 million equity raise in June 2026. This financial boost aims to fund its biosimilar pipeline and global expansion, addressing short-term liquidity concerns. However, investors are cautioned about the high-interest debt and existing leverage, especially given ongoing regulatory hurdles like the May 2026 FDA Form 483, which could impact product launch timings and milestone revenues.
Amgen (AMGN) Stock Is Up, What You Need To Know
Shares of biotech company Amgen (AMGN) rose by 3.1% after a federal judge in Colorado granted a preliminary injunction against the state's plan to impose a 70% price cap on its drug Enbrel, citing potential "economic injury" and federal law preemption. This ruling alleviates a significant pricing threat for Amgen's product. The stock's modest volatility suggests that while the news is meaningful, it doesn't fundamentally alter the market's long-term perception of the business, which recently saw a 6.4% gain following a $650 million investment in its US manufacturing network.
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs
Roche announced positive preliminary Phase 3 results for its KRAS G12C inhibitor, divarasib, for non-small cell lung cancer, claiming an advantage over existing drugs from Amgen and Bristol Myers Squibb. The company noted that divarasib met its primary and secondary endpoints with clinically meaningful and statistically significant improvements and no new safety signals. Roche plans to submit the data to regulators and present more detailed findings at a future medical conference, positioning divarasib as a potential new standard of care.
SLS - SELLAS Life Sciences Group Inc Options
This page provides a detailed financial overview of SELLAS Life Sciences Group Inc (SLS), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional ownership, profitability, and stock performance metrics over different periods. The data indicates recent strong performance with significant percentage increases over weeks, months, and quarters.
Amgen Inc Stock (AMGN) Moved Up by 3.01% on Jul 2: Key Drivers Unveiled
Amgen Inc. (AMGN) saw a 3.01% increase in its stock price on July 2, primarily driven by a federal judge's preliminary injunction blocking a proposed price cap on its key drug, Enbrel. This legal victory overshadowed concerns regarding data integrity for Tavneos and a Class II recall of Corlanor. Analysts remain optimistic about Amgen's long-term potential, focusing on pipeline drugs like MariTide and olpasiran, despite existing regulatory challenges and a leveraged balance sheet.
NVS - Novartis AG ADR Options
This page provides an extensive overview of Novartis AG (NVS) ADR options, detailing its financial performance, key ratios, stock performance metrics, and analyst recommendations. It includes data such as market capitalization, income, sales, dividend information, P/E ratios, and various growth rates.
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?
Mineralys Therapeutics, Inc. (MLYS) is highlighted as a promising biotech stock due to new data presented on lorundrostat's potential in addressing heart failure risk. The company also recently announced a public offering of 5.66 million shares at $26.50 each to fund a portion of a $200 million royalty obligation repurchase, strengthening its financial position for future growth. MLYS is a clinical-stage company developing therapies for aldosterone-driven diseases.
Vertrix Wealth Management LLC Buys New Position in Amgen Inc. $AMGN
Vertrix Wealth Management LLC has acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the first quarter, purchasing 15,456 shares valued at approximately $5.44 million. This investment now constitutes 2.0% of Vertrix's portfolio and is its 13th largest holding. Amgen continues to see strong institutional interest, with hedge funds and other investors collectively holding 76.5% of its stock.
Amgen Inc. $AMGN Stake Lessened by Fulton Bank N.A.
Fulton Bank N.A. decreased its stake in Amgen Inc. by 16.4% in the first quarter, selling 2,853 shares and holding 14,566 shares valued at $5.1 million. Despite this reduction, institutional ownership in Amgen remains high at 76.50%, with several other funds increasing their positions. Amgen also surpassed analyst expectations with its recent quarterly earnings, reporting an adjusted EPS of $5.15 and revenues of $8.62 billion against estimates of $4.77 and $8.58 billion, respectively.
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
PureTech Health announced that its Founded Entity Celea Therapeutics has completed a $180 million financing round with participation from top-tier healthcare investors, including RA Capital Management and Leaps by Bayer. This funding will enable Celea to initiate the Phase 3 SURPASS-IPF trial for deupirfenidone (LYT-100), aiming to establish it as a new standard of care for Idiopathic Pulmonary Fibrosis (IPF). PureTech will retain a significant ownership stake of 35.4% in Celea and is eligible for substantial royalties and milestone payments, reflecting its strategy of advancing programs to value-inflection points and creating independent entities with external capital.
IHE - iShares U.S. Pharmaceuticals ETF Earnings
This article provides detailed financial and performance data for the iShares U.S. Pharmaceuticals ETF (IHE). It covers key metrics such as last close price, dollar and percentage changes, dividend information, expense ratio, IPO date, and various performance returns over different periods. The data indicates strong recent performance, with a 1-year return of 55.23%.
